<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>37(1)</volume><submitter>Smith VL</submitter><pubmed_abstract>Dentatorubral-pallidoluysian atrophy (DRPLA) is a fatal neurodegenerative disease arising from a CAG repeat expansion in the atrophin-1 (&lt;i>ATN1&lt;/i>) gene. Because DRPLA, like many repeat expansion disorders (REDs), arises predominantly from toxic gain-of-function mechanisms, we hypothesized that &lt;i>ATN1&lt;/i> knockdown would have therapeutic potential. To test this, we established the first fully humanized mouse model of a RED, in which one allele of mouse &lt;i>Atn1&lt;/i> is completely replaced by human &lt;i>ATN1&lt;/i>, including 112 pure CAG repeats. This novel approach to exploring RED biology provides significant advantages, notably the ability to test sequence-specific therapeutics targeting human sequences, even in introns and untranslated regions of pre-mRNA. We found that our model-the &lt;i>At</pubmed_abstract><journal>Molecular therapy. Nucleic acids</journal><pagination>102815</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12857545</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Atrophin-1 antisense oligonucleotide provides robust protection from pathology in a fully humanized DRPLA model.</pubmed_title><pmcid>PMC12857545</pmcid><pubmed_authors>Greenfield J</pubmed_authors><pubmed_authors>Ben-Varon A</pubmed_authors><pubmed_authors>Khurana V</pubmed_authors><pubmed_authors>Zhao HT</pubmed_authors><pubmed_authors>Barker-Haliski M</pubmed_authors><pubmed_authors>Child DD</pubmed_authors><pubmed_authors>Carroll JB</pubmed_authors><pubmed_authors>Gidi BZ</pubmed_authors><pubmed_authors>Compton A</pubmed_authors><pubmed_authors>Cantle JP</pubmed_authors><pubmed_authors>Kordasiewicz HB</pubmed_authors><pubmed_authors>Yu T</pubmed_authors><pubmed_authors>Smith VL</pubmed_authors><pubmed_authors>Noble B</pubmed_authors><pubmed_authors>Gemos A</pubmed_authors><pubmed_authors>Prades S</pubmed_authors><pubmed_authors>Bragg RM</pubmed_authors><pubmed_authors>Korecka JA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Atrophin-1 antisense oligonucleotide provides robust protection from pathology in a fully humanized DRPLA model.</name><description>Dentatorubral-pallidoluysian atrophy (DRPLA) is a fatal neurodegenerative disease arising from a CAG repeat expansion in the atrophin-1 (&lt;i>ATN1&lt;/i>) gene. Because DRPLA, like many repeat expansion disorders (REDs), arises predominantly from toxic gain-of-function mechanisms, we hypothesized that &lt;i>ATN1&lt;/i> knockdown would have therapeutic potential. To test this, we established the first fully humanized mouse model of a RED, in which one allele of mouse &lt;i>Atn1&lt;/i> is completely replaced by human &lt;i>ATN1&lt;/i>, including 112 pure CAG repeats. This novel approach to exploring RED biology provides significant advantages, notably the ability to test sequence-specific therapeutics targeting human sequences, even in introns and untranslated regions of pre-mRNA. We found that our model-the &lt;i>At</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Mar</publication><modification>2026-06-18T05:48:05.49Z</modification><creation>2026-06-18T03:07:30.357Z</creation></dates><accession>S-EPMC12857545</accession><cross_references><pubmed>41624332</pubmed><doi>10.1016/j.omtn.2025.102815</doi></cross_references></HashMap>